Solventum (NYSE:SOLV – Get Free Report) and NeurAxis (NASDAQ:NRXS – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.
Valuation & Earnings
This table compares Solventum and NeurAxis”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Solventum | $8.31 billion | 1.79 | $1.56 billion | $8.18 | 10.70 |
| NeurAxis | $5.32 million | 16.37 | -$14.63 million | ($0.78) | -8.88 |
Profitability
This table compares Solventum and NeurAxis’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Solventum | 17.26% | 25.09% | 8.78% |
| NeurAxis | -492.76% | N/A | -641.25% |
Volatility & Risk
Solventum has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500. Comparatively, NeurAxis has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current recommendations for Solventum and NeurAxis, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Solventum | 1 | 3 | 10 | 0 | 2.64 |
| NeurAxis | 0 | 1 | 1 | 0 | 2.50 |
Solventum currently has a consensus target price of $92.80, indicating a potential upside of 6.04%. NeurAxis has a consensus target price of $13.00, indicating a potential upside of 87.59%. Given NeurAxis’ higher possible upside, analysts plainly believe NeurAxis is more favorable than Solventum.
Insider & Institutional Ownership
11.8% of NeurAxis shares are held by institutional investors. 0.2% of Solventum shares are held by company insiders. Comparatively, 21.1% of NeurAxis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
Solventum beats NeurAxis on 9 of the 14 factors compared between the two stocks.
About Solventum
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes. The Dental Solutions segment provides a comprehensive suite of dental and orthodontic products including brackets, aligners, restorative cements, and bonding agents. The Health Information Systems provides software solutions including computer-assisted, physician documentation, direct-to-bill and coding automation, classification methodologies, speech, recognition, and data visualization platforms. The Purification and Filtration segment provides purification and filtration technologies including filters, purifiers, cartridges, and membranes. The company was incorporated in 2023 and is based in Saint Paul, Minnesota.
About NeurAxis
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.
Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.
